PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
132 hedge funds and large institutions have $260M invested in PDL BioPharma, Inc. in 2020 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 57 reducing their positions, and 30 closing their positions.
152% more call options, than puts
Call options by funds: $252K | Put options by funds: $100K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
12% less funds holding
Funds holding: 150 → 132 (-18)
18% less capital invested
Capital invested by funds: $318M → $260M (-$58.6M)
47% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 57
50% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Silver Point Capital
Greenwich,
Connecticut
|
+$15.8M |
| 2 |
MAP
Madison Avenue Partners
New York
|
+$4.4M |
| 3 |
KIM
Kestrel Investment Management
San Mateo,
California
|
+$2.81M |
| 4 |
D.E. Shaw & Co
New York
|
+$875K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$588K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Engine Capital Management
New York
|
-$9.79M |
| 2 |
NM
Newtyn Management
New York
|
-$4.87M |
| 3 |
WG
Winton Group
London,
United Kingdom
|
-$4.21M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$2.76M |
| 5 |
BlackRock
New York
|
-$2.64M |
PDLI Hedge Fund Activity: Q1 2020 in Review
132 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q1 2020, worth a combined $260M — down 18% from $318M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of PDLI and 15 opened new positions — a net loss of 15 holders — while 57 trimmed existing stakes and 30 added.
The largest buyer was Silver Point Capital, opening a new position worth an estimated $15.8M. The largest seller was Engine Capital Management, cutting an estimated $9.79M.
- 132 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q1 2020, down from 150 in Q4 2019.
- Funds reported $260M of PDL BioPharma, Inc. stock for Q1 2020, down 18% quarter-over-quarter.
- 15 funds opened new PDL BioPharma, Inc. positions in Q1 2020 and 30 closed out, a net change of -15 holders.
- The largest PDL BioPharma, Inc. buyer in Q1 2020 was Silver Point Capital, an estimated $15.8M added.
- The largest PDL BioPharma, Inc. seller in Q1 2020 was Engine Capital Management, an estimated $9.79M sold.
Based on aggregated 13F filings for Q1 2020.